Protease-inhibitor boosting in the treatment-experienced patient

Joel E. Gallant

Research output: Contribution to journalArticle

Abstract

Highly active antiretroviral therapy (HAART) consisting of protease inhibitor (PI)-containing regimens has revolutionized the treatment options for HIV-infected individuals. However, even with successful treatment, virus is not completely eliminated, and virologic failure can occur because of treatment complexity, tolerability and side-effect issues, and suboptimal pharmacokinetics. Ritonavir-boosted PI therapies (i.e. combinations of low-dose ritonavir with a primary PI) can effectively enhance the pharmacokinetics of the primary PI by reducing its first-pass metabolism and postabsorptive clearance, thereby increasing potency. Boosted PI regimens may also simplify treatment by reducing regimen complexity and pill burden. For treatment-experienced patients, the higher PI concentrations achieved with ritonavir boosting may improve activity against PI-resistant virus. This article reviews the principles of PI boosting, its advantages and disadvantages, and the clinical experience with this strategy in treatment-experienced populations.

Original languageEnglish (US)
Pages (from-to)226-233
Number of pages8
JournalAIDS Reviews
Volume6
Issue number4
StatePublished - Oct 2004

Fingerprint

Protease Inhibitors
Ritonavir
Therapeutics
Pharmacokinetics
Viruses
Highly Active Antiretroviral Therapy
HIV
Population

Keywords

  • Boosting
  • Pharmacokinetics
  • Protease inhibitor
  • Ritonavir

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Protease-inhibitor boosting in the treatment-experienced patient. / Gallant, Joel E.

In: AIDS Reviews, Vol. 6, No. 4, 10.2004, p. 226-233.

Research output: Contribution to journalArticle

Gallant, JE 2004, 'Protease-inhibitor boosting in the treatment-experienced patient', AIDS Reviews, vol. 6, no. 4, pp. 226-233.
Gallant, Joel E. / Protease-inhibitor boosting in the treatment-experienced patient. In: AIDS Reviews. 2004 ; Vol. 6, No. 4. pp. 226-233.
@article{59246a8e6544459ea07a12502de33864,
title = "Protease-inhibitor boosting in the treatment-experienced patient",
abstract = "Highly active antiretroviral therapy (HAART) consisting of protease inhibitor (PI)-containing regimens has revolutionized the treatment options for HIV-infected individuals. However, even with successful treatment, virus is not completely eliminated, and virologic failure can occur because of treatment complexity, tolerability and side-effect issues, and suboptimal pharmacokinetics. Ritonavir-boosted PI therapies (i.e. combinations of low-dose ritonavir with a primary PI) can effectively enhance the pharmacokinetics of the primary PI by reducing its first-pass metabolism and postabsorptive clearance, thereby increasing potency. Boosted PI regimens may also simplify treatment by reducing regimen complexity and pill burden. For treatment-experienced patients, the higher PI concentrations achieved with ritonavir boosting may improve activity against PI-resistant virus. This article reviews the principles of PI boosting, its advantages and disadvantages, and the clinical experience with this strategy in treatment-experienced populations.",
keywords = "Boosting, Pharmacokinetics, Protease inhibitor, Ritonavir",
author = "Gallant, {Joel E.}",
year = "2004",
month = "10",
language = "English (US)",
volume = "6",
pages = "226--233",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "4",

}

TY - JOUR

T1 - Protease-inhibitor boosting in the treatment-experienced patient

AU - Gallant, Joel E.

PY - 2004/10

Y1 - 2004/10

N2 - Highly active antiretroviral therapy (HAART) consisting of protease inhibitor (PI)-containing regimens has revolutionized the treatment options for HIV-infected individuals. However, even with successful treatment, virus is not completely eliminated, and virologic failure can occur because of treatment complexity, tolerability and side-effect issues, and suboptimal pharmacokinetics. Ritonavir-boosted PI therapies (i.e. combinations of low-dose ritonavir with a primary PI) can effectively enhance the pharmacokinetics of the primary PI by reducing its first-pass metabolism and postabsorptive clearance, thereby increasing potency. Boosted PI regimens may also simplify treatment by reducing regimen complexity and pill burden. For treatment-experienced patients, the higher PI concentrations achieved with ritonavir boosting may improve activity against PI-resistant virus. This article reviews the principles of PI boosting, its advantages and disadvantages, and the clinical experience with this strategy in treatment-experienced populations.

AB - Highly active antiretroviral therapy (HAART) consisting of protease inhibitor (PI)-containing regimens has revolutionized the treatment options for HIV-infected individuals. However, even with successful treatment, virus is not completely eliminated, and virologic failure can occur because of treatment complexity, tolerability and side-effect issues, and suboptimal pharmacokinetics. Ritonavir-boosted PI therapies (i.e. combinations of low-dose ritonavir with a primary PI) can effectively enhance the pharmacokinetics of the primary PI by reducing its first-pass metabolism and postabsorptive clearance, thereby increasing potency. Boosted PI regimens may also simplify treatment by reducing regimen complexity and pill burden. For treatment-experienced patients, the higher PI concentrations achieved with ritonavir boosting may improve activity against PI-resistant virus. This article reviews the principles of PI boosting, its advantages and disadvantages, and the clinical experience with this strategy in treatment-experienced populations.

KW - Boosting

KW - Pharmacokinetics

KW - Protease inhibitor

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=13644249455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13644249455&partnerID=8YFLogxK

M3 - Article

C2 - 15700621

AN - SCOPUS:13644249455

VL - 6

SP - 226

EP - 233

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 4

ER -